Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-122.54	-131.12	52.23	-100.42	-114.94
Depreciation & Amortization	2.16	2.4	3.3	4.09	3.82
Stock-Based Compensation	20.28	16.4	9.65	8.75	6.74
Other Adjustments	3.36	2.65	12.3	7.07	8.42
Change in Receivables	-20	-	-	-	-
Changes in Accounts Payable	1.61	-0.03	-0.2	0.4	-3.78
Changes in Accrued Expenses	0.48	3.48	3.81	-5.09	4.83
Changes in Other Operating Activities	-6.61	-5.73	-5.13	-1.62	-4.29
Operating Cash Flow	-121.27	-111.94	75.95	-86.83	-99.2
Capital Expenditures	-0.59	-0.79	-1.15	-0.44	-1.97
Purchases of Investments	-144.49	-187.67	-	-	-
Proceeds from Sale of Investments	30	17.5	-	-	-
Other Investing Activities	-	-	-	-	-1.2
Investing Cash Flow	-164.39	-170.96	-1.15	-0.44	-3.17
Long-Term Debt Issued	39.4	-	-	-	-
Net Long-Term Debt Issued (Repaid)	39.4	-	-	-	-
Issuance of Common Stock	9.98	275.84	0.73	0.21	0.15
Net Common Stock Issued (Repurchased)	9.98	275.84	0.73	0.21	0.15
Issuance of Preferred Stock	-	-	70.79	-	-
Net Preferred Stock Issued (Repurchased)	-	-	70.79	-	-
Other Financing Activities	-1.12	-0.5	21.32	16.18	-
Financing Cash Flow	190.32	275.34	92.85	16.39	1.73
Net Cash Flow	-95.61	-7.57	167.65	-70.88	-100.65
Free Cash Flow	-121.86	-112.73	74.81	-87.27	-101.17
FCF Margin	-609.29%	-	44.66%	-	-
Free Cash Flow Per Share	-2.48	-2.62	27.40	-38.14	-50.36
Levered Free Cash Flow	-86.09	-131.78	4.03	-103.08	-116.32
Unlevered Free Cash Flow	-137	-143.56	56.95	-101.22	-112.41

Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q